Secretion of vascular endothelial growth factor in ovarian cancer

European Journal of Gynaecological Oncology

Volumn 20, Issue 3, 1999, Pages 177-181

  Santin, A D ^a,b,c   Hermonat, P L ^a   Ravaggi, A ^a,b   Cannon, M J ^a   Pecorelli, S ^b   Parham, G P ^a  

^a UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF ARKANSAS MEDICAL CENTER   (United States)

Author keywords

Dendritic cells; Ovarian cancer; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN;

ADULT; AGED; ARTICLE; ASCITES FLUID; CARCINOMA CELL; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; OVARY CARCINOMA;

ADULT; ASCITIC FLUID; DENDRITIC CELLS; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; LYMPHOKINES; MIDDLE AGED; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032989564     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. DiSaia P. J., Creasman W. T.: "Epithelial ovarian cancer". In: DiSaia P. J., Creasman W. T. (eds.), "Clinical Gynecologic Oncology". St. Louis, Mosby - Year Book, Inc. 1993, 333.
2. Cappuccini F., Yamamoto R. S., DiSaia P. J., Grosen E. A., Gatanaga M., Lucci J. A. et al.: "Identification of tumor necrosis factor and lympotoxin blocking factor(s) in the ascites of patients with advanced and recurrent ovarian cancer". Lymphokine and Cytokine Research, 1991, 10, 225.
3. Badger A., Oh S., Moolten F.: "Differential effects of an immunosuppressive fraction from ascites fluid of patients with ovarian cancer on spontaneous and antibody dependent cytotoxicity". Cancer Res., 1981, 41, 1133.
4. Berek J. S., Bast R. C., Lichtensteint A., Hacker N. F., Spina C. A., Lagasse L. D. et al.: "Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer". Obstet. Gynecol., 1984, 64, 708.
5. Granger G., Gatanaga T., Burger R., Grosen E., DiSaia P.: "TNF, LT, and IL-1 natural inhibitors (soluble receptors and receptor antagonists) in women with ovarian cancer". In: "Ovarian Cancer 3". (eds. F. Sharp, W. P. Mason, T. Blackett, J. Berek), Chapman & Hall, London, 1995, 115.
6. Hirte H., Clark D. A.: "Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: identification of transforming growth factor & as a suppressive factor". Cancer Immunol. Immunother., 1991, 32, 296.
7. Gotlieb W. H., Abrams J. S., Watson J. M., Velu T. J., Berek J. S., Martinez-Maza O.: "Presence of IL-10 in the ascites of patients with ovarian and other intra-abdominal cancers". Cytokine, 1992, 4, 385.
8. Berek J. S., Martinez-Maza O.: "Molecular and biologic factors in the pathogenesis of ovarian cancer". J. Reproductive Medicine, 1994, 39, 241.
9. Luo J. C., Yamaguchi S., Shinkai A., Shitara K., Shibuya M.: "Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors". Cancer Res., 1998, 58, 2652.
10. Folkman J., Klagsburn M.: "Angiogenic factors". Science, 1987, 235, 442.
11. Ferrara N., Davis-Smyth T.: "The biology of vascular endothelial growth factor". Endocr. Review, 1997, 18, 4.
12. Gabrilovich D. J., Chen H. L., Girgis K. R., Cunningham T., Meny G. M., Nadaf S. et al.: "Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells". Nature Med., 1996, 2, 1096.
13. Boocock C. A., Charnock-Jones S., Sharkey A. M., McLaren J., Barker P. J., Wright K. A. et al.: "Expression of vascular endothelial growth factor and its receptor fit and KDR in ovarian carcinomas". J. Natl. Cancer Inst., 1995, 87, 506.
14. Yoneda J., Kuniyasu H., Crispens M. A., Price J. E., Bucana C. D., Fidler I. J.: "Expression of angiogenesis-related genes and progression in human ovarian carcinomas in nude mice". J. Natl. Cancer Inst., 1998, 90, 447.
15. Fuchtner C., Emma D. A., Manetta A., Gamboa G., Bernstein R., Liao S. Y.: "Characterization of a human ovarian carcinoma cell line: UCI 101". Gynecol. Oncol., 1993, 48, 203.
16. Gamboa-Vujicic G., Carpenter P., Podnos Y. D., Dorion G., Iravani L., Bolton D. et al.: "Characterization and development of UCI 107: s primary human ovarian carcinoma cell line". Gynecol. Oncol., 1995, 58, 336.
17. De Martin R., Haendler B., Hofer-Warbinex R., Gaugitsch H., Wrann M., Schlusenere H. et al.: "Complementary DNA for human glioblastoma-derived T cell suppressor factor β, a novel member of the transforming growth factor-β family". EMBO J., 1987, 6, 3673.
18. Toi M., Hoshima S., Takayanagi T., Tominaga T.: "Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer". Jpn J. Cancer Res., 1994, 85, 1045.
19. Maeda K., Chung Y. S., Ogawa Y., Takatsuka S., Kang S. M., Ogawa M. et al.: "Prognostic value of vascular endothelial growth factor expression in gastric carcinoma". Cancer, 1996, 77, 858.
20. Takahashi Y., Clearly K. R., Mai M., Kitadai Y., Bucana C. D., Ellis L. M.: "Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer". Clin. Cancer Res., 1996, 2, 1679.
21. Takahashi Y., Kitadai Y., Bucana C. D., Clearly K. R., Ellis L. M.: "Expression of vascular endothelial growth factor and its receptor, KDR, correlated with vascularity, metastasis, and proliferation of human colon cancer". Cancer Res., 1995, 55, 3964.
22. Weidner N., Semple J. P., Welch W. R., Folkman J.: "Tumor angiogenesis and metastasis-correlation in invasive breast cancer". N. Engl. J. Med., 1991, 324, 1.
23. Huang A. Y. C., Golumbek P., Ahmadzadeh M., Jaffee E., Pardoll D., Levitsky H.: "Role of bone-marrow-derived cells in presenting MHC class I-restricted tumor antigens". Science, 1994, 264, 961.
24. Young J. W., Inaba K.: "Dendritic cells as adjuvants for Class I major hystocompalibility complex-restricted antitumor immunity". J. Exp. Med., 1996, 183, 7.
25. Oyama T., Ran S., Ishida T., Nadaf S., Kerr L., Carbone D. P. et al.: "Vascular endothelial growth factor affects dendritic cells maturation through the inhibition of nuclear factor-kB activation in hemopoietic progenitor cells". J. Immunol., 1998, 160, 1224.
26. Akhurst R. J., Fitzpatrick D. R., Gatherer D., Lehnert S. A., Millan F. A.: "Transforming growth factor-βs in mammalian embryogenesis". Prog. Growth Factor Res., 1991, 2, 153.
27. Berger D. P., Herbstritt L., Dengler W. A., Marme D., Mertelsmann R., Fiebig H. H.: "Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies". Ann. Oncol., 1995, 6, 817.
28. Dirix L. Y., Vermeulen P. B., Hubens G., Benoy I., Martin M., De Pooter C., Van Oosterom A. T.: "Serum basic fibroblast growth factor and vascular endothelial growth factor and tumor growth kinetics in advanced colorectal cancer". Ann. Oncol., 1996, 7, 843.
29. Freeman M. R., Schneck F. X., Gagnon M. L., Corless C., Soker S., Niknejad K. et al.: "Pheriperal blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis". Cancer Res., 1995, 55, 4140.
30. Borgstrom P., Bourdon M. A., Hillan K. J., Sriramarao P., Ferrara N.: "Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo". The Prostate, 1997, 35, 1.